Yu-Chong Peng
Overview
Explore the profile of Yu-Chong Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu J, Su Y, Chen Y, Huang Y, Chen Z, Peng Y, et al.
Ann Med
. 2025 Jan;
57(1):2456113.
PMID: 39865865
Background And Aims: Hepatocellular carcinoma (HCC) recurrence was previously characterized into four types, and patients with progression/hyper-progression recurrence (type III-IV) have an extremely poor prognosis. However, the immune background of...
2.
Xu J, Chen Y, Qi L, Peng Y
Endocrine
. 2024 Jul;
87(1):196-205.
PMID: 39075276
Purpose: A potential association between breast (BC) and thyroid cancer (TC) has been observed. We investigated if the relationship between BC and TC is causal using bidirectional Mendelian randomization (MR)...
3.
Xu J, Zhu Q, Bi Y, Peng Y
BMC Cancer
. 2024 Jun;
24(1):691.
PMID: 38844880
Purpose: The potential efficacy of metformin in breast cancer (BC) has been hotly discussed but never conclusive. This genetics-based study aimed to evaluate the relationships between metformin targets and BC...
4.
Peng Y, Xu J, You X, Huang Y, Ma L, Li L, et al.
Ann Med
. 2023 Dec;
55(2):2283160.
PMID: 38112540
Background: We aimed to assess differences in intestinal microflora between patients with operable hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) with microvascular invasion (MVI) and those without MVI. Additionally, we investigated...
5.
Xu J, Qin S, Wei H, Chen Y, Peng Y, Qi L
Ann Med
. 2023 Apr;
55(1):2199219.
PMID: 37070467
Purpose: The purpose of this study was to estimate the clinical efficacy and identify the best beneficiaries of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in hepatocellular carcinoma (HCC). Patients And...
6.
Xu J, Qin S, Wei H, Chen Y, Peng Y, Qi L
Clin Sci (Lond)
. 2023 Feb;
137(4):303-316.
PMID: 36749124
Background: Postoperative transarterial chemoembolization (PA-TACE) is an effective adjuvant therapy for preventing early postoperative recurrence of hepatocellular carcinoma (HCC); however, many patients are insensitive to it. Therefore, the present study...
7.
Qi L, Ma L, Wu F, Chen Y, Xu J, Peng Y, et al.
Liver Int
. 2022 Jul;
42(10):2283-2298.
PMID: 35810457
Background & Aims: The multiplicity of hepatocellular carcinoma (HCC) recurrence patterns is the most important determinant of patients' postsurgical survival. A systematic HCC recurrence classification is needed to help prevent...
8.
Peng Y, Xu J, Zeng C, Zhao X, Li L, Qi L
Ann Transl Med
. 2022 Jun;
10(10):549.
PMID: 35722392
Background: Hepatitis B virus-related hepatocellular carcinoma (B-HCC) negatively affects the gut microbiome. This study aimed to investigate the gut microbiome profiles and functions post-hepatectomy liver failure (PHLF) after extended hepatectomy...
9.
Peng Y, Xu J, Zeng C, Zhao X, You X, Xu P, et al.
Ann Transl Med
. 2022 May;
10(8):477.
PMID: 35571398
Background: Age was important prognostic factors for operable hepatocellular carcinoma patients. The aim of the present study was to assess the difference in gut microbiota in patients with operable hepatitis...
10.
Peng Y, Zhao X, Zeng C, Xu J, Qi L, Li L
J Gastrointest Oncol
. 2022 Mar;
13(1):326-343.
PMID: 35284109
Background: This study sought to evaluate the association between intestinal and post-hepatectomy liver failure (PHLF) in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (B-HCC), and identify the inner relationship....